Poly-α(1→4)glucopyranose Matrices with Hydrazide Crosslinking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hydrogel matrices face challenges such as uncontrolled degradation, lack of durability, and inadequate drug release profiles, which can lead to adverse biological responses and ineffective therapeutic outcomes due to rapid drug depletion and fragmentation.
Innovation Solution
Development of biocompatible, biodegradable matrices formed from poly-α(1→4)glucopyranose with hydrazide crosslinking, allowing for controlled enzymatic degradation and sustained release of bioactive agents, while maintaining physical integrity and biocompatibility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If hydrogel matrices are made biodegradable, then they can be broken down in the body, but they degrade too rapidly and cause matrix fragmentation and loss of embolic matrix fragments into the circulatory system
Solution Approach 1:
The patent changes the chemical parameters of the hydrogel matrix by incorporating ester linkages with controlled hydrolysis rates and adjusting the crosslinking density to achieve desired degradation profiles. This allows tuning the degradation time from rapid to controlled, preventing matrix fragmentation while maintaining biodegradability.
Solution Approach 2:
The patent creates composite hydrogel structures combining different polymeric materials with varying degradation rates. By layering or mixing materials with different stability characteristics, the matrix achieves both initial structural integrity and controlled degradation, preventing premature fragmentation while allowing eventual breakdown.
2Quantity of substance
If hydrogel matrices are made highly hydrophilic, then they can absorb water and swell, but they cause plasticization of the polymer, resulting in a soft gel-like matrix that can tear upon expansion and ruin its physical integrity
Solution Approach 1:
The patent designs the hydrogel matrix with a flexible yet strong network structure that can accommodate water absorption and swelling without tearing. By optimizing the polymer network architecture and crosslinking density, the matrix maintains physical integrity during expansion while still achieving the desired hydrophilic properties and water absorption capacity.
3Ease of manufacture
If chemical agents are used to cure the polymeric materials, then the hydrogel matrices can be formed, but the chemical agents can cause tissue damage
Solution Approach 1:
The patent replaces chemical curing agents with physical crosslinking mechanisms such as ionic crosslinking, hydrogen bonding, or photo-induced crosslinking. This substitution eliminates or reduces the need for potentially harmful chemical agents while maintaining the ability to form and cure the hydrogel matrix effectively.
4Reliability
If hydrogel matrices are designed for drug release, then they can provide therapeutic effect, but the majority of the agent is released in a short burst, resulting in depletion of the agent and therapeutically ineffective rate
Solution Approach 1:
The patent segments the drug release mechanism into multiple phases by creating heterogeneous matrix structures with different polymer compositions, crosslinking densities, or pore sizes. This segmentation allows different portions of the drug load to be released at different rates, transforming a single burst release into a sustained, multi-phase release profile that maintains therapeutically effective concentrations over extended periods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The matrices provide a stable, biocompatible platform for sustained bioactive agent release, promoting tissue healing and regeneration with reduced adverse reactions, and maintaining cellular viability and function.
Implementation Method 1
reactive hydrazide groups, which are used to form the linking groups of the crosslinked matrix
Implementation Method 2
control over their rate of degradation in vivo, thereby allowing for sustained release of the bioactive agent
Data Source
AI summary
The present invention provides biocompatible, biodegradable matrices formed from poly-α(1→4)glucopyranose and reactive hydrazide groups. The matrices can be used for various applications in the body, including drug delivery and cell therapy.